Previous 10 | Next 10 |
BeiGene (NASDAQ: BGNE) , is a Chinese biopharmaceutical company with offices in Cambridge, Massachusetts; Basel, Switzerland; and Beijing. It focuses on unique therapies to treat cancer, specializing in B-cell malignancies and solid tumors in lung and gastrointestinal cancers. A...
Accepted presentations to showcase broad and deep development programs targeting B-cell and myeloid malignancies 15 accepted abstracts, including three oral presentations for cornerstone BTKi, BRUKINSA ® , and promising Bcl-2 inhibitor, BGB-11417 BeiGene, (N...
The European Commission (EC) approved the expanded use of BeiGene's ( NASDAQ: BGNE ) medicine Brukinsa to treat adult patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy. BeiGene sa...
BRUKINSA is the first and only Bruton’s Tyrosine Kinase (BTK) inhibitor for marginal zone lymphoma approved in the European Union BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the European Commission (EC) has gr...
Summary Baillie Gifford’s 13F portfolio value decreased from ~$97.51B to ~$96.99B this quarter. They increased Shopify, Roblox, Zoom Video, and Twilio while reducing Albemarle Corporation and Li Auto ADR. The top three positions are Tesla Motors, Moderna, and MercadoLib...
BeiGene ( NASDAQ: BGNE ) said its medicine Brukinsa received marketing authorization to treat certain rare blood cancers in six countries in Central and South America. In Argentina Brukinsa received approval to treat relapsed/refractory (r/r) mantle cell lymphoma ...
BRUKINSA ® received Marketing Authorization as a treatment for rare blood cancers in six countries in Central and South America BeiGene, (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing innovative and affordable ...
Summary HQH is able to generate strong and steady yield which is good enough to ignore the price loss suffered by this fund in a market that’s bearish overall. HQH is in a better position to hold up to its current price, and as it trades at a good discount to its NAV, chanc...
Summary China pharma company Jinxi Jemincare out-licensed global rights for its androgen receptor degrader to Roche in a $650 million agreement. The oral small-molecule candidate, developed in Jemincare’s R&D center, is currently in preclinical testing. Shanghai IASO Bi...
A committee of the European Medicines Agency (EMA) recommended the approval of BeiGene ( NASDAQ: BGNE ) Brukinsa (zanubrutinib) to treat adult patients with chronic lymphocytic leukemia (CLL). The positive opinion by the EMA's Committee for Medicinal Products...
News, Short Squeeze, Breakout and More Instantly...
$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ann...
2024-07-20 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the C...